Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643010 | 0.86 | ALDH1A1 (0.43) | MAP3K12PIK3CAMTORALOX5APFEN1 | |
| SCHEMBL17547699 | 0.86 | HSP90AA1 (0.42) | ALOX5APHSP90AA1 | |
| SCHEMBL20458857 | 0.82 | MAP3K12 (0.39) | MAP3K12PIK3CAMTORALOX5APFEN1 | |
| SCHEMBL16852159 | 0.78 | AGBL2 (0.34) | HSP90AA1 | |
| SCHEMBL19628512 | 0.78 | POLB (0.33) | HSP90AA1 | |
| SCHEMBL19370437 | 0.77 | PIK3CD (0.46) | CYP3A4 | |
| SCHEMBL10197339 | 0.77 | HSP90AA1 (0.36) | HSP90AA1 | |
| SCHEMBL11890838 | 0.76 | NOS3 (0.54) | MAP3K12PIK3CAMTOR | |
| SCHEMBL5560254 | 0.76 | ALOX5AP (0.46) | ALOX5APFEN1HSP90AA1 | |
| SCHEMBL21590041 | 0.75 | KMT2A (0.42) | ALOX5APHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440951-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | MAP3K12 1964/4885PIK3CA 1113/4885MTOR 3231/4885 |
| US-20150239865-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAP3K12 2848/4885PIK3CA 1889/4885MTOR 4375/4885 |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | MAP3K12 154/4885PIK3CA 126/4885MTOR 470/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAP3K12 2848/4885PIK3CA 1889/4885MTOR 4375/4885 |
| US-20160340314-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAP3K12 2848/4885PIK3CA 1889/4885MTOR 4375/4885 |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | MAP3K12 21/4885PIK3CA 2/4885MTOR 1/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MAP3K12 190/4885PIK3CA 8/4885MTOR 28/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | MAP3K12 190/4885PIK3CA 8/4885MTOR 28/4885 |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MAP3K12 190/4885PIK3CA 8/4885MTOR 28/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | MAP3K12 62/4885PIK3CA 2/4885MTOR 1/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | MAP3K12 2750/4885PIK3CA 1999/4885MTOR 4421/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAP3K12 2801/4885PIK3CA 1909/4885MTOR 4370/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAP3K12 2848/4885PIK3CA 1889/4885MTOR 4375/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | MAP3K12 2892/4885PIK3CA 1963/4885MTOR 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.